Treating Advanced and Radioactive Iodine-Refractory Thyroid Cancer With Jochen Lorch, MD

Dr. Jochen Lorch, MD, MSc, is a Professor of Medicine and Medical Oncologist specializing in head, neck, and thyroid cancers at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Dr. Lorch discusses the challenges of selecting treatment for advanced thyroid cancers, the importance of molecular testing for selection of kinase inhibitors in thyroid cancers, and future directions of research in thyroid cancer treatment selection and sequencing.  

FDA Approves Nivolumab as Neoadjuvant Therapy for Resectable Non–Small Cell Lung Cancer

 The FDA has approved nivolumab (Opdivo®, Bristol-Myers Squibb) in combination with platinum doublet chemotherapy for the treatment of adult patients with early-stage, resectable non–small cell lung cancer (NSCLC). Nivolumab is a fully human programmed cell death ligand 1 (PD-L1)–targeted antibody, and its use is approved without regard for PD-L1 expression level. "In patients with nonmetastatic NSCLC, surgery has curative potential, but 30% to 80% who undergo resection experience recurrenc...

Pacritinib Approved for Intermediate- or High-Risk Myelofibrosis With Thrombocytopenia

The FDA has approved pacritinib (VonjoTM, CTI BioPharma) for the treatment of adult patients with intermediate- to high-risk primary or secondary myelofibrosis with a platelet count below 50x109/L. Pacritinib is a novel oral kinase inhibitor which inhibits Janus kinase 2 (JAK2) with minimal myelosuppression. Previous treatments available for intermediate- and high-risk myelofibrosis have not been approved for patients with severe cytopenia. "Pacritinib can provide a treatment option for patients...

FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma

The FDA has approved pembrolizumab (Keytruda®, Merck), a programmed death cell death protein 1 (PD-1)–blocking antibody, for the adjuvant treatment of adult and pediatric patients 12 years and older with stage IIB or IIC melanoma following complete resection. "Current standard of care for patients after resection of high-risk stage II melanoma is observation," wrote Jason Luke, MD, Director of the Cancer Immunotherapeutics Center in the Division of Hematology/Oncology at the University of Pittsb...

Copyright © 2022 Oncology Data Advisor. All rights reserved.